Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots?
Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots?
复制标题
DOI：
10.1002/stem.1452
复制
发表时间：
2013-10-01
期刊：
影响因子：
5.2
通讯作者：
Ritter, Thomas
中科院分区：
文献类型：
--
作者：
Griffin, Matthew D.;Elliman, Stephen J.;Ritter, Thomas
间充质干细胞(MSCs)一直是学术界和业界研究人员关注的重点领域，他们的共同目标是扩大其对各种炎症和免疫介导性疾病的治疗用途。最近，该领域的科学出版、临床试验活动和商业化的速度加快。这包括报告了四个领域令人振奋的新发展，这四个领域将对未来在大量患者中成功使用基于MSC的疗法至关重要：(A)在培养中产生MSCs的骨髓和其他组织中初级细胞的基础生物学。(B)骨髓间充质干细胞在体内调节免疫和炎症反应的机制。(C)深入了解MSC在相关动物疾病模型中的动力学、安全性和有效性。(D)生物医学公司和学术医学中心对人类间充质干细胞的分离、定义和基于临床试验的测试。尽管取得了这一进展，但在可预见的未来，骨髓间充质干细胞是否会作为药物治疗或外科/放射治疗的常用替代方案进入主流治疗实践仍不清楚。在这篇综述中，我们总结了有助于将MSC研究转化为临床领域的四个领域中每一个领域的一些最重要的新进展。在这一最新进展的背景下，我们讨论了关键的挑战和具体的知识差距，如果不以协调的方式加以解决，可能会阻碍为巩固以MSC为基础的疗法的地位而建立强有力的“转换管道”。干细胞2013；31：2033-2041
Mesenchymal stromal (stem) cells (MSCs) continue to be a strong area of focus for academic- and industry-based researchers who share the goal of expanding their therapeutic use for diverse inflammatory and immune-mediated diseases. Recently, there has been an accelerated rate of scientific publication, clinical trial activity, and commercialisation in the field. This has included the reporting of exciting new developments in four areas that will be of key importance to future successful use of MSC-based therapies in large numbers of patients: (a) fundamental biology of the primary cells in bone marrow and other tissues that give rise to MSCs in culture. (b) Mechanisms by which MSCs modulate immune and inflammatory responses in vivo. (c) Insights into MSC kinetics, safety, and efficacy in relevant animal disease models. (d) Isolation, definition, and clinical trial-based testing of human MSCs by biomedical companies and academic medical centers. Despite this progress, it remains unclear whether MSCs will enter mainstream therapeutic practice as a frequently used alternative to pharmacotherapy or surgical/radiological procedures in the foreseeable future. In this review, we summarize some of the most significant new developments for each of the four areas that contribute to the process of translating MSC research to the clinical arena. In the context of this recent progress, we discuss key challenges and specific knowledge gaps which, if not addressed in a coordinated fashion, may hinder the creation of robust "translational pipelines" for consolidating the status of MSC-based therapies. Stem Cells 2013;31:2033-2041